The importance of combined radiation and endocrine therapy in locally advanced prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 2, 2012, Pages 245-246

  Gray, Phillip J ^a,b   Shipley, William U ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84858041983     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.177     Document Type: Review

References (18)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC et al. Population-based prostatespecific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int 2009; 104: 1592-8.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9. (Pubitemid 41095147)
4. Payne HA, Gillatt DA. Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 2007; 99: 545-53. (Pubitemid 46238826)
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74. (Pubitemid 28445094)
6. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC et al. Updated nomogram to predict pathologic stage of prostate cancer given prostatespecific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101. (Pubitemid 46891611)
7. Roach M 3rd, Chen A, Song J, Diaz A, Presti J Jr et al. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol 2000; 18: 108-14. (Pubitemid 30395859)
8. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-21. (Pubitemid 27106285)
9. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-91. (Pubitemid 351264352)
10. Bolla M, Collette L, Blank L, Warde P, Dubois JB et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
11. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8. (Pubitemid 46606211)
12. Warde P, Mason M, Ding K, Kirkbride P, Brundage M et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet; e-pub ahead of print 3 November 2011; doi:10.1016/S0140-6736(11)61095-7.
13. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8.
14. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, MachtayM et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11. (Pubitemid 46606377)
15. Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-55. (Pubitemid 47418390)
16. Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/ SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009; 10: 370-80.
17. Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 437-44.
18. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 685-91.